Schizophrenia is a complex mental health condition. 

While antipsychotic medications are often effective at managing the positive symptoms of schizophrenia (such as hallucinations and delusions), enabling many patients to lead fulfilling lives, a significant challenge remains: the negative symptoms. 

These can include a range of issues like emotional unresponsiveness, difficulty with cognitive and social skills, and a lack of energy or motivation (lethargy).

Currently, there are no medications specifically approved by the FDA to treat these negative symptoms, and even newer generation drugs haven't shown significant improvement in this area.

It's crucial to understand that these negative symptoms not only lead to a decline in quality of life but can also hinder the effectiveness of other psychological and psychiatric treatments that often complement medication therapy.

Given that schizophrenia is associated with hypofrontality (reduced activity in the frontal lobe of the brain), repeated stimulation of the prefrontal regions and the deeper brain networks connected to them, potentially through methods like Deep TMS, might have long-term effects on neuronal excitability. 

This could offer an effective way to address the severe negative symptoms of schizophrenia. 

Additionally, many individuals with schizophrenia experience auditory hallucinations, which are another area of focus for treatment.

This therapy works by delivering magnetic stimulation to specific brain structures and networks that are believed to be responsible for the negative symptoms of schizophrenia, leading to significant improvement for patients.

This treatment has several advantages: it's an outpatient procedure, meaning it doesn't require hospitalization or anesthesia.

It's generally well-tolerated and comes with minimal systemic side effects.

Deep TMS treatment for schizophrenia (specifically targeting negative symptoms) is approved by the CE and ANIVISA.

You are viewing a page that is not intended for persons in the United States, and includes information about treatment applications that HAVE NOT BEEN CLEARED by the FDA for safety and efficacy.

However, BrainsWay Deep TMS™ has received the European CE Mark for the treatment of many conditions.

This significant approval underscores the therapy's established safety and efficacy for these indications in Europe. While regulatory statuses vary by region, this CE Mark highlights the recognized potential of Deep TMS as a therapeutic option for:

Major Depressive Disorder (MDD)

Anxiety Depression

Obsessive-Compulsive Disorder (OCD)

Smoking Cessation

Alzheimer's Disease (AD)

Autism

Bipolar Disorder

Chronic Pain

Multiple Sclerosis (MS)

Parkinson's Disease

Post-Stroke Rehabilitation

Post-Traumatic Stress Disorder (PTSD)

Negative Symptoms of Schizophrenia